{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:12:59Z","timestamp":1782933179305,"version":"3.54.5"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Addressing lymphopenia in cancer patients has been suggested as a novel immunotherapeutic strategy. As interleukin\u20107 (IL\u20107) is necessary for proliferation of lymphocytes and to increase total lymphocyte count (TLC), IL\u20107 therapy has been attempted in various cancers. Here, we describe the clinical results of treatment of recurrent glioblastoma (GBM) with a long\u2010acting engineered version of recombinant human IL\u20107 (rhIL\u20107\u2010hyFc).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective case series based on compassionate use was approved by the Ministry of Food and Drug Safety in South Korea. Primary outcomes were safety profile and TLC. Secondary outcomes were overall survival (OS) and progression\u2010free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 18 patients enrolled, 10 received rhIL\u20107\u2010hyFc with temozolomide, 5 received rhIL\u20107\u2010hyFc with bevacizumab, 1 received rhIL\u20107\u2010hyFc with PCV chemotherapy, and 2 received rhIL\u20107\u2010hyFc alone. Mean TLC of the enrolled patients after the first rhIL\u20107\u2010hyFc treatment increased significantly from 1131\u2009cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      (330\u20132989) at baseline to 4356\u2009cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      (661\u201322,661). Higher TLCs were maintained while rhIL\u20107\u2010hyFc was repeatedly administered. Median OS and PFS were 378\u2009days (107\u2013864\u2009days) and 231\u2009days (55\u2013726\u2009days), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study reports that IL\u20107 immunotherapy can restore and maintain TLC during treatment with various salvage chemotherapies in recurrent GBM patients without serious toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.5467","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T06:40:21Z","timestamp":1672382421000},"page":"6778-6787","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Compassionate use of recombinant human\n                    <scp>IL\u20107\u2010hyFc<\/scp>\n                    as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6854-1597","authenticated-orcid":false,"given":"Stephen","family":"Ahn","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Seoul St. Mary's Hospital College of Medicine, The Catholic University of Korea  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae\u2010Sung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Seoul St. Mary's Hospital College of Medicine, The Catholic University of Korea  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heewon","family":"Kim","sequence":"additional","affiliation":[{"name":"Genexine, Inc.  Seongnam\u2010si Gyeonggi\u2010do South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minkyu","family":"Heo","sequence":"additional","affiliation":[{"name":"Genexine, Inc.  Seongnam\u2010si Gyeonggi\u2010do South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Chul","family":"Sung","sequence":"additional","affiliation":[{"name":"Genexine, Inc.  Seongnam\u2010si Gyeonggi\u2010do South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8421-6455","authenticated-orcid":false,"given":"Sin\u2010Soo","family":"Jeun","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Seoul St. Mary's Hospital College of Medicine, The Catholic University of Korea  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab200"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.18718"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707358"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa106"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103226"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2019.11.017"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1256-6"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-019-03167-2"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.1053"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0549-5"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00457-z"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902593"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2970"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv173"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000210386.55951.c2"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1303"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2550"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12800"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0238-9"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms160510267"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/15476910903453296"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1953"},{"key":"e_1_2_10_24_1","first-page":"1714","article-title":"A human recombinant IL\u20107\/HGF\u03b2 hybrid cytokine enhances antitumor immunity in mice","volume":"7","author":"Han F","year":"2017","journal-title":"Am J Cancer Res"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0423"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.01.002"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1024"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.5467","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:02:17Z","timestamp":1698638537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.5467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/cam4.5467"],"URL":"https:\/\/doi.org\/10.1002\/cam4.5467","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.01.09.22268651","asserted-by":"object"}]},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]},"assertion":[{"value":"2022-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}